Oppenheimer Starts Amarin Corporation (AMRN) at Underperform, $7 PT

Go back to Oppenheimer Starts Amarin Corporation (AMRN) at Underperform, $7 PT

Gilead Sciences (GILD) 'Quietly' Added Amarin's (AMRN) Vascepa to an Old NASH Combo Trial - Raymond James

November 19, 2019 5:38 PM EST

Raymond James analyst Steven Seedhouse highlighted that Gilead Sciences (NASDAQ: GILD) has "quietly" added Amarin's (NASDAQ: AMRN) Vascepa to an old NASH combo trial.

The analyst commented, "We recently noticed a change to the clinical... More

Amarin Corp. (AMRN) Declines After Shares Hit with 'Underperform' Rating

November 19, 2019 4:29 PM EST

Amarin Corp. (NASDAQ: AMRN) declined post-market-close Tuesday after the stock was initiated with an Underperform rating and a price target of $7 at Oppenheimer. The stock declined about 3.5%.

... More